Abstract:Objective: Inspired by the traditionally clinical application of herb pair Zhimu-Huangbo to treat diabetes, a combination of plant ingredients, timosaponin B2 (TB-2) and berberine (BBR), was evaluated for their anti-diabetic efficacy and cooperative mechanisms. Methods: The efficacy and pharmacokinetics of orally administered TB-2 (33.3 mg/kg/day), BBR (66.7 mg/kg/day), and TB-2+BBR (100 mg/kg/day) were evaluated in spontaneously non-obese diabetic Goto-Kakizaki (GK) rats, and metformin (200 mg/kg/day) was used as a positive control. The comparative exposure of the parent drugs, timosaponin A3 (TB-2 metabolite), and M1–M5 (BBR metabolites) was quantified in the portal vein plasma (before hepatic disposition), liver, and systemic plasma (after hepatic disposition) of normal rats on single and combination treatments. Cooperative mechanism of TB-2 and BBR on intestinal absorption and hepatic metabolism was investigated in Caco-2 cells and primary hepatocytes, respectively. Results: After a 6-week experiment, non-fasting and fasting blood glucose levels and oral glucose tolerance test results showed that TB-2+BBR treatments (100 mg/kg/day) displayed significantly anti-diabetic efficacy in GK rats, comparable to that on metformin treatments. However, no significant improvement was observed on TB-2 or BBR treatments alone. Compared to single treatments, combination treatments led to the increased circulating levels of BBR by 107% in GK rats. In normal rats, the hepatic exposure of BBR, timosaponin A3, and M1–M5 was several hundred folds higher than their circulating levels. Co-administration also improved the levels in the plasma and liver by 41–114% for BBR, 141–230% for TB-2, and 12–282% for M1–M5. In vitro, the interaction between TB-2 and BBR was mediated by intestinal absorption, rather than hepatic metabolism. Conclusion: Combining TB-2 and BBR enhanced the anti-diabetic efficacy by increasing the in vivo variety of effective substances, including the parent compounds and active metabolites, and improving the levels of those substances through intestinal absorption. This study is a new attempt to assess the effects of combined plant ingredients on diabetes by scientifically utilizing clinical experience of an herb pair.

Combined Contributions of Impaired Hepatic CYP2C11 and Intestinal Breast Cancer Resistance Protein Activities and Expression to Increased Oral Glibenclamide Exposure in Rats with Streptozotocin-Induced Diabetes Mellitus

Combined Contribution Of Increased Intestinal Permeability And Inhibited Deglycosylation Of Ginsenoside Rb1 In The Intestinal Tract To The Enhancement Of Ginsenoside Rb1 Exposure In Diabetic Rats After Oral Administration

Tissue-specific Damage in Expression and Function of Breast Cancer Resistance Protein in Streptozotocin-Induced Diabetic Rats

Impaired Expression and Function of Breast Cancer Resistance Protein (bcrp) in Brain Cortex of Streptozocin-Induced Diabetic Rats.

The gut microbiota contributes to the modulation of intestinal CYP3A1 and P-gp in streptozotocin-induced type 1 diabetic rats

Opposite Regulation of Hepatic Breast Cancer Resistance Protein in Type 1 and 2 Diabetes Mellitus.

Impairment of Intestinal Monocarboxylate Transporter 6 Function and Expression in Diabetic Rats Induced by Combination of High-Fat Diet and Low Dose of Streptozocin: Involvement of Butyrate–Peroxisome Proliferator-Activated Receptor-γ Activation

Dmd064881 1702..1710

Impaired function and expression of P-glycoprotein in blood-brain barrier of streptozotocin-induced diabetic rats.

Tissue-specific Alterations in Expression and Function of P-glycoprotein in Streptozotocin-Induced Diabetic Rats

Increased plasma exposures of five protoberberine alkaloids from coptidis rhizoma in streptozotocin-induced diabetic rats: Is PGP involved?

Type 2 Diabetes Mellitus Decreases Systemic Exposure of Clopidogrel Active Metabolite Through Upregulation of P-glycoprotein in Rats.

Induction of multidrug resistance-associated protein 2 in liver, intestine and kidney of streptozotocin-induced diabetic rats.

Impaired Hepatic and Intestinal ATP-binding Cassette Transporter G5/8 Was Associated with High Exposure of Β-Sitosterol and the Potential Risks to Blood–brain Barrier Integrity in Diabetic Rats

Effects of 18alpha-glycyrrhizin on the pharmacodynamics and pharmacokinetics of glibenclamide in alloxan-induced diabetic rats.

Insulin Therapy Restores Impaired Function and Expression of P-glycoprotein in Blood–brain Barrier of Experimental Diabetes

Prediction of Atorvastatin Pharmacokinetics in High-Fat Diet and Low-Dose Streptozotocin-Induced Diabetic Rats Using a Semiphysiologically Based Pharmacokinetic Model Involving Both Enzymes and Transporters

Effects of glucose and insulin on expression and function of bile acid transporters in sandwich cultured rat hepatocytes

Opposite effect of diabetes mellitus induced by streptozotocin on oral and intravenous pharmacokinetics of verapamil in rats.

Enhanced Anti-diabetic Effect of Berberine Combined with Timosaponin B2 in Goto-Kakizaki Rats, Associated with Increased Variety and Exposure of Effective Substances Through Intestinal Absorption

Effects of different doses glimepiride intake on the pharmacokinetics of benzbromarone in rats